Solid growth for Japanese Rx market despite March disaster
This article was originally published in Scrip
The lack of a general biennial price revision this April helped Japan's prescription market grow by 5.3% to ¥2,313.8 billion ($30.2 billion) at official reimbursement prices in the three months to 30 June, with new diabetes therapies providing much of the impetus.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.